{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:21:36Z","timestamp":1793154096141,"version":"4.5.0"},"reference-count":36,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) has transitioned from an underdiagnosed condition to a rapidly evolving therapeutic frontier. This review highlights the expanding treatment landscape, beginning with evidence from key clinical trials for transthyretin tetramer stabilizers and RNA silencers, and extending to novel therapies including gene-editing agents and monoclonal antibody-based fibril depleters. We summarize pivotal trial data \u2013 including the ATTR-ACT, HELIOS-B, and APOLLO-B trials \u2013 and describe ongoing investigations aimed at broadening therapeutic options. Practical considerations such as route and frequency of administration, tolerability, and regulatory status are outlined to support clinical decision-making. A dedicated section on limitations and special populations addresses the generalizability of trial findings to the diverse patients encountered in practice. Finally, we explore key unresolved questions, including the need for head-to-head comparative trials, the potential role of combination therapy, and the optimal timing for initiating treatment as earlier recognition becomes more common. As novel therapies gain approval this review serves as a timely, focused resource to support clinicians managing ATTR-CM.<\/jats:p>","DOI":"10.15420\/usc.2025.11","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:46:18Z","timestamp":1761907578000},"source":"Crossref","is-referenced-by-count":8,"title":["Transthyretin Amyloid Cardiomyopathy: The Plot Thickens as Novel Therapies Emerge"],"prefix":"10.15420","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-0134","authenticated-orcid":false,"given":"Michelle","family":"Dimza","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-7020","authenticated-orcid":false,"given":"Georgia","family":"Vasilakis","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-3196","authenticated-orcid":false,"given":"Justin L","family":"Grodin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref0","unstructured":"Ioannou A, Massa P, Patel RK, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J 2023;44:2893\u2013907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347; PMID:\u00a037216684."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Aus dem Siepen F, Hein S, Bauer R, et al. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid 2017;24(Suppl 1):132\u20133. https:\/\/doi.org\/10.1080\/13506129.2016.1272453; PMID:\u00a028434295.","DOI":"10.1080\/13506129.2016.1272453"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 2020;142:e7\u201322. https:\/\/doi.org\/10.1161\/CIR.0000000000000792; PMID:\u00a032476490.","DOI":"10.1161\/cir.0000000000000792"},{"key":"ref3","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785\u201392. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1; PMID:\u00a022843282."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689; PMID:\u00a030145929.","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Zhou S, Ge S, Zhang W, et al. Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis. ACS Chem Neurosci 2020;11:3025\u201335. https:\/\/doi.org\/10.1021\/acschemneuro.0c00338; PMID:\u00a032915538.","DOI":"10.1021\/acschemneuro.0c00338"},{"key":"ref6","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024;390:132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2305434; PMID:\u00a038197816."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Judge DP, Alexander KM, Cappelli F, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2025;85:1003\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.042; PMID:\u00a040074465.","DOI":"10.1016\/j.jacc.2024.11.042"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Judge DP, Gillmore JD, Alexander KM, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation 2025;151:601\u201311. https:\/\/DOI.ORG\/10.1161\/CIRCULATIONAHA.124.072771; PMID:\u00a039556242.","DOI":"10.1161\/CIRCULATIONAHA.124.072771"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014;59:1144\u201365. https:\/\/doi.org\/10.1002\/hep.26972; PMID:\u00a024716201.","DOI":"10.1002\/hep.26972"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Judge DP, Kristen AV, Grogan M, et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther 2020;34:357\u201370. https:\/\/doi.org\/10.1007\/s10557-019-06919-4; PMID:\u00a032062791.","DOI":"10.1007\/s10557-019-06919-4"},{"key":"ref11","unstructured":"Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023;389:1553\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2300757; PMID:\u00a037888916."},{"key":"ref12","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 2025;392:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134; PMID:\u00a039213194."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337:816\u201321. https:\/\/doi.org\/10.1126\/science.1225829; PMID:\u00a022745249.","DOI":"10.1126\/science.1225829"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021;385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454; PMID:\u00a034215024.","DOI":"10.1056\/NEJMoa2107454"},{"key":"ref15","unstructured":"Gustavsson A, Engstr\u00f6m U, Westermark P. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 1994;144:1301\u201311. PMID:\u00a08203468."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Goldsteins G, Persson H, Andersson K, et al. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc Natl Acad Sci U S A 1999;96:3108\u201313. https:\/\/doi.org\/10.1073\/pnas.96.6.3108; PMID:\u00a010077645.","DOI":"10.1073\/pnas.96.6.3108"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 2016;23:86\u201397. https:\/\/doi.org\/10.3109\/13506129.2016.1148025; PMID:\u00a026981744.","DOI":"10.3109\/13506129.2016.1148025"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Suhr OB, Grogan M, Silva AMD, et al. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid 2025;32:14\u201321. https:\/\/doi.org\/10.1080\/13506129.2024.2420809; PMID:\u00a039472768.","DOI":"10.1080\/13506129.2024.2420809"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun 2021;12:3142. https:\/\/doi.org\/10.1038\/s41467-021-23274-x; PMID:\u00a034035264.","DOI":"10.1038\/s41467-021-23274-x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med 2023;389:239\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2303765; PMID:\u00a037212440.","DOI":"10.1056\/nejmoa2303765"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Fontana M, Gilbertson J, Verona G, et al. Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy. N Engl J Med 2023;388:2199\u2013201. https:\/\/doi.org\/10.1056\/NEJMc2304584; PMID:\u00a037285532.","DOI":"10.1056\/nejmc2304584"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Wall JS, Martin EB, Lands R, et al. Cardiac amyloid detection by PET\/CT imaging of iodine (124I) evuzamitide (124I-p5+14): a phase 1\/2 study. JACC Cardiovasc Imaging 2023;16:1433\u201348. https:\/\/doi.org\/10.1016\/j.jcmg.2023.08.009; PMID:\u00a037940323.","DOI":"10.1016\/j.jcmg.2023.08.009"},{"key":"ref23","unstructured":"Fontana MGJD, Selvanayagam J, Korczyk D, et al. Phase 2 clinical trial design of AT-02 Phase 2 open-label extension study in systemic amyloidosis. Presented at: XIX International Symposium on Amyloidosis, Rochester, MN, May 26\u201330, 2024."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Porcari A, Razvi Y, Masi A, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2023;25:515\u201324. https:\/\/doi.org\/10.1002\/ejhf.2776; PMID:\u00a036644836.","DOI":"10.1002\/ejhf.2776"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 2012;109:9629\u201334. https:\/\/doi.org\/10.1073\/pnas.1121005109; PMID:\u00a022645360.","DOI":"10.1073\/pnas.1121005109"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Rapezzi C, Elliott P, Damy T, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail 2021;9:115\u201323. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.011; PMID:\u00a033309574.","DOI":"10.1016\/j.jchf.2020.09.011"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Morfino P, Aimo A, Panichella G, et al. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail Rev 2022;27:2187\u2013200. https:\/\/doi.org\/10.1007\/s10741-022-10237-7; PMID:\u00a035386059.","DOI":"10.1007\/s10741-022-10237-7"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A 2013;110:9992\u20137. https:\/\/doi.org\/10.1073\/pnas.1300761110; PMID:\u00a023716704.","DOI":"10.1073\/pnas.1300761110"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Grodin JL. Transthyretin amyloid cardiomyopathy: wherever protein stabilization leads, disease stabilization follows. J Am Coll Cardiol 2025;85:1015\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2025.01.008; PMID:\u00a040074466.","DOI":"10.1016\/j.jacc.2025.01.008"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Grodin JL, Maurer MS. The truth is unfolding about transthyretin cardiac amyloidosis. Circulation 2019;140:27\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041015; PMID:\u00a031549879.","DOI":"10.1161\/CIRCULATIONAHA.119.041015"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Fail Rev 2025;30:69\u201373. https:\/\/doi.org\/10.1007\/s10741-024-10444-4; PMID:\u00a039354201.","DOI":"10.1007\/s10741-024-10444-4"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"ACC Expert Consensus Writing Committee. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2023;81:1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022; PMID:\u00a036697326.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 2020;13:1299\u2013310. https:\/\/doi.org\/10.1016\/j.jcmg.2020.03.010; PMID:\u00a032498919.","DOI":"10.1016\/j.jcmg.2020.03.010"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Pedretti R, Wang L, Hanna M, et al. Detection of circulating transthyretin amyloid aggregates in plasma: a novel biomarker for transthyretin amyloidosis. Circulation 2024;149:1696\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067225; PMID:\u00a038768274.","DOI":"10.1161\/circulationaha.123.067225"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Martin EB, Stuckey A, Powell D, et al. Clinical confirmation of pan-amyloid reactivity of radioiodinated peptide 124I-p5+14 (AT-01) in patients with diverse types of systemic amyloidosis demonstrated by PET\/CT imaging. Pharmaceuticals (Basel) 2023;16:629. https:\/\/doi.org\/10.3390\/ph16040629; PMID:\u00a037111386.","DOI":"10.3390\/ph16040629"}],"container-title":["US Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2025.11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:46:20Z","timestamp":1761907580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2025.11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":36,"URL":"https:\/\/doi.org\/10.15420\/usc.2025.11","relation":{},"ISSN":["1758-390X","1758-3896"],"issn-type":[{"value":"1758-390X","type":"electronic"},{"value":"1758-3896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"e21"}}